Keyphrases
Ovarian Cancer
100%
Taxanes
100%
Antivascular Therapy
100%
Metronomic Chemotherapy
100%
Maximum Tolerated Dose
75%
AEE788
75%
Tumor
50%
Epidermal Growth Factor Receptor
50%
Microvessel Density
50%
Combination Therapy
50%
Cell-free DNA (cfDNA)
50%
Docetaxel
50%
Clinical Trials
25%
Tumor Growth
25%
Targeted Tumor
25%
Chemotherapy Resistance
25%
Overall Survival
25%
Endothelial Cells
25%
Chemotherapy
25%
Additive Effect
25%
Tumor-specific
25%
Chemotherapy Alone
25%
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Assay
25%
Apoptotic Index
25%
Vascular Endothelial Growth Factor Receptor (VEGFR)
25%
Tumor Endothelial Cells
25%
Transferases
25%
Proliferative Index
25%
Proliferating Cell nuclear Antigen
25%
End-labelling
25%
Cell Toxicity
25%
Dosing Regimen
25%
Cytotoxic Effect
25%
CD31
25%
Orthotopic Model
25%
Proliferation Index
25%
Vascular Endothelial Growth Factor Receptor Inhibitor
25%
Deoxyribonucleotides
25%
Endothelial Precursors
25%
Modulating Effect
25%
Nuclear Apoptosis
25%
Taxane Chemotherapy
25%
Endothelial Tumors
25%
Metronomic Dosing
25%
Medicine and Dentistry
Neoplasm
100%
Ovarian Cancer
100%
6 [4 (4 Ethyl 1 Piperazinylmethyl)phenyl] 4 (Alpha Methylbenzylamino) 7h pyrrolo[2,3 D]pyrimidine
100%
Endothelial Cell
66%
Combination Therapy
66%
Epidermal Growth Factor Receptor
66%
Vasculotropin Receptor
66%
Cytotoxicity
66%
Microvessel
66%
Docetaxel
66%
Cell-Free DNA
66%
In Vitro
33%
Clinical Trial
33%
Overall Survival
33%
Precursor
33%
Drug Dose Regimen
33%
Low Drug Dose
33%
Programmed Cell Death
33%
Cell Line
33%
Specific Tumor
33%
Tumor Progression
33%
MTT Assay
33%
TUNEL Assay
33%
Proliferating Cell Nuclear Antigen
33%
Transferase
33%
Deoxyribonucleotide
33%
Chemotherapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Ovary Cancer
100%
Taxane
83%
Neoplasm
66%
Maximum Tolerated Dose
50%
6 [4 (4 Ethyl 1 Piperazinylmethyl)phenyl] 4 (Alpha Methylbenzylamino) 7h pyrrolo[2,3 D]pyrimidine
50%
Combination Therapy
33%
Epidermal Growth Factor Receptor
33%
Vasculotropin Receptor
33%
Docetaxel
33%
Cytotoxicity
33%
Clinical Trial
16%
Tumor Growth
16%
Mouse Model
16%
Overall Survival
16%
3 (4,5 Dimethyl 2 Thiazolyl) 2,5 Diphenyltetrazolium Bromide
16%
Cycline
16%
Transferase
16%
Deoxyribonucleotide
16%